Suppr超能文献

肾细胞癌:根治性手术对局部或远处复发不同模式的作用。

Renal cell carcinoma: The role of radical surgery on different patterns of local or distant recurrence.

机构信息

General Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.

Unit of Oncology 2, University Hospital of Pisa, Italy.

出版信息

Surg Oncol. 2020 Dec;35:106-113. doi: 10.1016/j.suronc.2020.08.002. Epub 2020 Aug 13.

Abstract

INTRODUCTION

With the increasing reliance on targeted therapies and immunotherapy, no standard management strategy is today available for the treatment of locally, distant, or both renal cell carcinoma (RCC) recurrences, and their surgical treatment seems to play a crucial role. We report the 20-year experience of our center evaluating the short- and long-term outcomes of patients undergone surgical resection of RCC recurrences, and the possible role of repeated surgical resections of RCC recurrences.

MATERIALS AND METHODS

From January 1999 to January 2019, 40 patients underwent surgical resection of isolated locally recurrent RCC (iLR-RCC-group), locally recurrent RCC associated with the presence of distant recurrence (LR-DR-RCC-group), and distant-only recurrent RCC (DR-RCC-group). Data regarding pre-, intra-, post-operative course, and follow-up, prospectively collected in an institutional database, were retrospectively analyzed and compared.

RESULTS

iLR-RCC-group was composed of 9 patients, LR-DR-RCC-group of 6 patients, and DR-RCC-group of 25 patients. The recurrence rate was 55.6% (5/9 patients) in iLR-RCC-group, 50% (3/6 patients) in LR-DR-RCC-group, and 44% (11/25) patients in DR-RCC-group, p = 0.830. 3/5 (60%) patients in iLR-RCC-group, 2/3 (66.7%) patients in LR-DR-RCC-group, and 7/11 (63.6%) patients in DR-RCC group underwent to almost one further local treatments of their recurrences, respectively (p = 0.981). No differences in the mean disease-free survival (p = 0.384), overall survival (OS) (p = 0.881), and cancer-specific survival (p = 0.265) were reported between the three groups. In DR-RCC-group, patients who underwent further local treatments of new recurrences presented a longer OS: 150.7 versus 66.5 months (p = 0.004).

CONCLUSIONS

A surgical resection of RCC recurrences should be always taken in consideration, also in metastatic patients and/or in those who have already undergone surgery of previous RCC recurrence, whenever radicality is still possible, because this approach may offer a potentially long survival.

摘要

简介

随着靶向治疗和免疫疗法的应用日益增多,目前对于局部、远处或两者均有的肾细胞癌(RCC)复发患者,尚无标准的治疗策略,而手术治疗似乎起着至关重要的作用。我们报告了本中心 20 年来评估接受 RCC 复发手术切除患者的短期和长期结果,并探讨了多次重复手术切除 RCC 复发的可能性。

材料与方法

从 1999 年 1 月至 2019 年 1 月,40 例患者接受了孤立性局部复发性 RCC(iLR-RCC 组)、局部复发性 RCC 合并远处转移(LR-DR-RCC 组)和远处复发性 RCC(DR-RCC 组)的手术切除治疗。回顾性分析了前瞻性收集于机构数据库中的患者术前、术中和术后病程及随访资料,并进行了比较。

结果

iLR-RCC 组 9 例,LR-DR-RCC 组 6 例,DR-RCC 组 25 例。iLR-RCC 组的复发率为 55.6%(5/9 例),LR-DR-RCC 组为 50%(3/6 例),DR-RCC 组为 44%(11/25 例),p=0.830。iLR-RCC 组 3/5(60%)例、LR-DR-RCC 组 2/3(66.7%)例和 DR-RCC 组 7/11(63.6%)例患者再次接受局部治疗,分别(p=0.981)。三组间无无疾病生存率(p=0.384)、总生存率(OS)(p=0.881)和癌症特异性生存率(p=0.265)差异。在 DR-RCC 组中,接受新复发性局部治疗的患者 OS 更长:150.7 个月 vs 66.5 个月(p=0.004)。

结论

对于 RCC 复发患者,只要根治性切除仍有可能,就应始终考虑手术切除,即使是转移患者和/或已行 RCC 复发手术切除的患者,因为这种方法可能提供潜在的长期生存。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验